VACCINE COMPOSITIONS AND METHODS OF USE
The present disclosure provides vaccine compositions comprising at least one adjuvant and at least one antigen, wherein the adjuvant is a cationic lipid. The disclosure also provides methods of treating a disease in a mammal, methods of preventing a disease in a mammal, and methods of effecting antigen cross presentation to induce a humoral immune response and a cellular immune response in a mammal utilizing the vaccine compositions. Cross presentation of various antigens can be achieved by formulating the specific antigens with cationic lipids possessing adjuvant properties.
1 . A vaccine composition comprising at least one adjuvant and at least one pathogenic antigen, wherein the adjuvant is a cationic lipid.
2 . The vaccine composition of claim 1 wherein the cationic lipid is a non-steroidal cationic lipid.
3 . The vaccine composition of claim 1 wherein the cationic lipid is selected from the group consisting of DOTAP, DOTMA, DOEPC, and combinations thereof.
4 . The vaccine composition of claim 1 wherein the adjuvant is an enantiomer of the cationic lipid.
5 . The vaccine composition of claim 4 wherein the enantiomer is R-DOTAP or S-DOTAP.
6 . The vaccine composition of claim 1 wherein one or more antigens is a viral antigen.
7 . The vaccine composition of claim 1 wherein one or more antigens is a bacterial or fungal antigen.
8 . The vaccine composition of claim 1 wherein at least one antigen is an antigen from a conserved region of a pathogen.
9 . The vaccine composition of claim 8 wherein the vaccine composition is a universal vaccine.
10 . The vaccine composition of claim 7 wherein the vaccine composition is an influenza vaccine, and wherein the influenza vaccine comprises a glycoprotein antigen found on the surface of an influenza virus.
11 . The vaccine composition of claim 10 wherein the antigen is a hemagglutinin antigen.
12 . The vaccine composition of claim 11 wherein the hemagglutinin antigen comprises an epitope region HA 818-526 .
13 . The vaccine composition of claim 10 wherein the influenza vaccine is a neuraminidase subunit vaccine.
14 . A method of effecting antigen cross presentation to induce a humoral immune response and a cellular immune response in a mammal, said method comprising the step of administering an effective amount of a vaccine composition to the mammal, wherein the vaccine composition comprises at least one adjuvant and at least one antigen, and wherein the adjuvant is a cationic lipid.
15 . The method of claim 14 wherein the humoral immune response is an antibody response.
16 . The method of claim 14 wherein the cellular immune response is a T cell response.
17 . The method of claim 16 wherein the T cell response is a CD 8+ T cell response.
18 . The method of claim 14 wherein the cationic lipid is a non-steroidal cationic lipid.
19 . The method of claim 14 wherein the cationic lipid is selected from the group consisting of DOTAP, DOTMA, DOEPC, and combinations thereof.
20 . The method of claim 14 wherein the adjuvant is an enantiomer of a cationic lipid.
21 - 30 . (canceled)